CreativeOne Wealth LLC Takes $869,000 Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

CreativeOne Wealth LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 39,413 shares of the company's stock, valued at approximately $869,000.

Several other institutional investors have also recently made changes to their positions in TEVA. Oarsman Capital Inc. bought a new stake in Teva Pharmaceutical Industries during the fourth quarter worth about $29,000. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries in the 3rd quarter worth approximately $50,000. Ameliora Wealth Management Ltd. purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter worth approximately $66,000. IFP Advisors Inc grew its position in Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after acquiring an additional 1,960 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its stake in shares of Teva Pharmaceutical Industries by 27.7% during the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after acquiring an additional 949 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on TEVA shares. Piper Sandler increased their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. StockNews.com cut Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Monday, April 14th. Barclays decreased their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. Bank of America reduced their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Finally, UBS Group lowered their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Trading Up 3.0 %

NYSE TEVA traded up $0.42 on Wednesday, hitting $14.42. The company's stock had a trading volume of 2,988,978 shares, compared to its average volume of 9,901,629. The firm has a market cap of $16.35 billion, a P/E ratio of -9.94, a PEG ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 52-week low of $12.47 and a 52-week high of $22.80. The company's 50-day simple moving average is $15.33 and its 200 day simple moving average is $17.62. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.